Virchows Archiv

, Volume 459, Issue 1, pp 41–46 | Cite as

Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia

  • Takeshi G. Kashima
  • Arunthati Dongre
  • Adrienne M. Flanagan
  • Pancras C. W. Hogendoorn
  • Richard Taylor
  • Nicholas A. Athanasou
Original Article


Adamantinoma of long bones (ALB) and osteofibrous dysplasia (OFD) are rare osteolytic bone tumours that principally arise in the tibia. Both ALB and OFD contain epithelial and stromal elements, as well as areas of fibro-osseous proliferation. We assessed expression of podoplanin, a glycoprotein found in osteocytes, in OFD and ALB as well as in fibrous dysplasia and metastatic cancer. Forty-two cases of ALB and OFD, 20 cases of fibrous dysplasia and 20 cases of metastatic carcinoma to bone were stained by immunohistochemistry for expression of podoplanin, epithelial (cytokeratin, epithelial membrane antigen) and vascular (CD34, LYVE-1) markers. Podoplanin was expressed in epithelial cells and tumour glands in ALB as well as in scattered intertrabecular stromal cells in both ALB and OFD. Podoplanin was not expressed by intertrabecular stromal cells in fibrous dysplasia or in metastatic adenocarcinoma. Podoplanin was expressed by osteocytes but not osteoblasts of woven and lamellar bone trabeculae in ALB, OFD, fibrous dysplasia and skeletal metastases. The finding of a common osteocyte marker in OFD/ALB stromal cells is in keeping with a close histogenetic relationship between OFD and ALB; this may reflect the prominence of fibro-osseous proliferation in these tumours. The expression of podoplanin in an osteolytic tumour of the tibia may be useful as a diagnostic discriminant in distinguishing OFD from fibrous dysplasia and ALB from metastatic adenocarcinoma.


Podoplanin Osteofibrous dysplasia Adamantinoma of long bone Fibrous dysplasia Bone tumour Metastasis 



The authors would like to thank Chris Lowe for typing the manuscript. This study was carried out by the EuroBoNet consortium, a Network of Excellence funded by the European Union.

Conflicts of interest

We declare that we have no conflicts of interest.


  1. 1.
    Hogendoorn PCW, Hashimoto H (2002) Adamantinoma. In: Fletcher C, Unni K, Mertens F (eds) Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon, pp 332–334Google Scholar
  2. 2.
    Unni KK, Inwards YI, Bridge AN, Kindblom LG, Wold EW (2005) Tumors of the bones and joints AFIP atlas of tumor pathology. AFIP, pp. 281–298Google Scholar
  3. 3.
    Vigorita VJ, Whelman B, Hogendoorn PCW (2002) Osteofibrous dysplasia. In: Fletcher C, Unni K, Mertens F (eds) Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon, pp 332–334Google Scholar
  4. 4.
    Benassi MS, Campanacci L, Gamberi G, Ferrari C, Picci P, Sangiorgi L, Campanacci M (1994) Cytokeratin expression and distribution in adamantinoma of the long bones and osteofibrous dysplasia of tibia and fibula. An immunohistochemical study correlated to histogenesis. Histopathology 25:71–76PubMedCrossRefGoogle Scholar
  5. 5.
    Hazelbag HM, Fleuren GJ, Van den Broek LJCM, Taminiau AHM, Hogendoorn PCW (1993) Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis. Am J Surg Pathol 17:1225–1233PubMedCrossRefGoogle Scholar
  6. 6.
    Ishida T, Iijima T, Kikuchi F, Kitagawa T, Tanida T, Imamura T, Machinami R (1992) A clinicopathological and immunohistochemical study of osteofibrous dysplasia, differentiated adamantinoma, and adamantinoma of long bones. Skeletal Radiol 21:493–502PubMedGoogle Scholar
  7. 7.
    Hazelbag HM, Taminiau AHM, Fleuren GJ, Hogendoorn PCW (1994) Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior. J Bone Joint Surg Am 76:1482–1499PubMedGoogle Scholar
  8. 8.
    Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D (1997) Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151:1141–1152PubMedGoogle Scholar
  9. 9.
    Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMedCrossRefGoogle Scholar
  10. 10.
    Rishi AK, Joyce-Brady M, Fisher J, Dobbs LG, Floros J, VanderSpek J, Brody JS, Williams MC (1995) Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol 167:294–306PubMedCrossRefGoogle Scholar
  11. 11.
    Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M (1996) Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18:125–132PubMedCrossRefGoogle Scholar
  12. 12.
    Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166:913–921PubMedCrossRefGoogle Scholar
  13. 13.
    Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, Yamada A, Yamane Y, Hishida T, Nishimura M, Yoshida J, Ikeda N, Ochiai A (2009) Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 100:2054–2059PubMedCrossRefGoogle Scholar
  14. 14.
    Ariizumi T, Ogose A, Kawashima H, Hotta T, Li GD, Xu YJ, Umezu H, Sugai M, Endo N (2010) Expression of podoplanin in human bone and bone tumors: new marker of osteogenic and chondrogenic bone tumors. Pathol Int 60:193–202PubMedCrossRefGoogle Scholar
  15. 15.
    Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M (2006) Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448:493–499PubMedCrossRefGoogle Scholar
  16. 16.
    Edwards JR, Williams K, Kindblom LG, Meis-Kindblom JM, Hogendoorn PCW, Hughes D, Forsyth RG, Jackson D, Athanasou NA (2008) Lymphatics and bone. Hum Pathol 39(1):49–55PubMedCrossRefGoogle Scholar
  17. 17.
    Kalof AN, Cooper K (2009) D2–40 immunohistochemistry–so far! Adv Anat Pathol 16:62–64PubMedCrossRefGoogle Scholar
  18. 18.
    Kimura N, Kimura I (2005) Podoplanin as a marker for mesothelioma. Pathol Int 55:83–86PubMedCrossRefGoogle Scholar
  19. 19.
    Gonzalez-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, Yoshida N, Kikuchi K, Ide F, Sakashita H, Kusama K (2010) Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med 39:103–109PubMedCrossRefGoogle Scholar
  20. 20.
    Czerniak B, Rojas-Corona RR, Dorfman HD (1989) Morphologic diversity of long bone adamantinoma. The concept of differentiated (regressing) adamantinoma and its relationship to osteofibrous dysplasia. Cancer 64:2319–2334PubMedCrossRefGoogle Scholar
  21. 21.
    Springfield DS, Rosenberg AE, Mankin HJ, Mindell ER (1994) Relationship between osteofibrous dysplasia and adamantionma. Clin Orthop Relat Res 309:234–244PubMedGoogle Scholar
  22. 22.
    Kempson RL (1966) Ossifying fibroma of the long bones. A light and electron microscopic study. Arch Pathol 82:218–233PubMedGoogle Scholar
  23. 23.
    Campbell CJ, Hawk T (1982) A variant of fibrous dysplasia (osteofibrous dysplasia). J Bone Joint Surg Am 64:231–236PubMedGoogle Scholar
  24. 24.
    Hopyan S, Gokgoz N, Bell RS, Andrulis IL, Alman BA, Wunder JS (1999) Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours. J Orthop Res 17:633–638PubMedCrossRefGoogle Scholar
  25. 25.
    Bovee JVMG, van den Broek LJCM, de Boer WI, Hogendoorn PCW (1998) Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. J Pathol 184:24–30PubMedCrossRefGoogle Scholar
  26. 26.
    Hazelbag HM, Van den Broek LJCM, Fleuren GJ, Taminiau AHM, Hogendoorn PCW (1997) Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation. Hum Pathol 28:183–188PubMedCrossRefGoogle Scholar
  27. 27.
    Lichtenstein L (1997) Dermal inclusion tumours in bone (so-called adamantinoma of limb bones). In: Lichtenstein L (ed) Bone Tumours. C.V. Mosby Co., St. Louis, pp 355–362Google Scholar
  28. 28.
    Povysil C, Matejovsky Z (1981) Ultrastructure of adamantinoma of long bones. Virchows Arch A Pathol Anat Histol 393:233–244PubMedCrossRefGoogle Scholar
  29. 29.
    Wicki A, Christofori G (2007) The potential role of podoplanin in tumour invasion. Br J Cancer 96:1–5PubMedCrossRefGoogle Scholar
  30. 30.
    Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9:261–272PubMedCrossRefGoogle Scholar
  31. 31.
    Maki M, Athanasou N (2004) Osteofibrous dysplasia and adamantinoma: correlation of proto-oncogene product and matrix protein expression. Hum Pathol 35:69–74PubMedCrossRefGoogle Scholar
  32. 32.
    Durchdewald M, Guinea-Viniegra J, Haag D, Riehl A, Lichter P, Hahn M, Wagner EF, Angel P, Hess J (2008) Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res 68:6877–6883PubMedCrossRefGoogle Scholar
  33. 33.
    Maki M, Saitoh K, Kaneko Y, Fukayama M, Morohoshi T (2000) Expression of cytokeratin 1, 5, 14, 19 and transforming growth factors-beta1, beta2, beta3 in osteofibrous dysplasia and adamantinoma: a possible association of transforming growth factor-beta with basal cell phenotype promotion. Pathol Int 50:801–807PubMedCrossRefGoogle Scholar
  34. 34.
    Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M (2007) Frequent immunoexpression of TGF-beta1, FGF-2 and BMP-2 in fibroblast-like cells in osteofibrous dysplasia. Oncol Rep 17:531–535PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Takeshi G. Kashima
    • 1
  • Arunthati Dongre
    • 1
  • Adrienne M. Flanagan
    • 2
  • Pancras C. W. Hogendoorn
    • 3
  • Richard Taylor
    • 1
  • Nicholas A. Athanasou
    • 1
  1. 1.Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal ScienceUniversity of Oxford, Nuffield Orthopaedic CentreOxfordUK
  2. 2.Histopathology DepartmentRoyal National Orthopaedic HospitalLondonUK
  3. 3.Department of PathologyLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations